Background: The WHO 2016 molecular classification corroborating with the histology has given more significant diagnostic objectivity to the diagnosis of brain tumors and it is more reliable for instituting therapy as the heterogeneity and observer subjectivity are bypassed with the addition of isocitrate dehydrogenase, ATRX, and 1p19q, and other molecular markers. Aim: Our aim is to review the histopathology of diagnosed brain tumors and correlate with immunohistochemical (IHC) findings to note for any disparity to reform the diagnosis in order to benefit the patient and report to the clinician if any treatment change is to be considered. Materials and Methods: This article is based on studies of screening and diagnostic test. A total of 150 brain tumors were retrospectively analyzed. Age, gender, and the tumor histological type and grade were systematically recorded. We compared our histopathological diagnosis before the introduction of the WHO 2016 molecular classification of central nervous system tumors and later after the relevant IHC and fluorescence in situ hybridization studies. Statistical Analysis: The statistical analysis was done by using Statistical Package for Social Sciences version recent for Windows. Results: Out of the total 150 brain tumor patients, 65 were males and 45 were females. About 37 were glial and the rest were in other categories. Conclusions: The molecular diagnosis that substantiated with the histomorphology is more objective and beneficial in the treatment of the patients.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.